Validity of Dot ELISA using crude somatic antigen of cholangiocarcinoma tumor mass

Abstract

OBJECTIVE

to investigate the validity of Dot ELISA using crude somatic antigen of cholangiocarcinoma (CCA) tumor mass.

METHODS

The cross-sectional diagnostic study was performed in patients who admitted at Khon Kaen Hospital, Thailand between October 2016 and March 2017. The overall patients enrolled to collect serum sample was 196 cases. The CHM1, a new prepared somatic antigen was collected and extracted from a liver tumor of one patient which clinically and histopathology confirmed as CCA. The enzyme-linked immunosorbent assay (ELISA) was performed to evaluate the diagnostic performance of reaction with that CHM1 crude somatic antigen.

RESULTS

There were 12 sera of proven CCA which nine sera gave positive results with Dot ELISA. For the 40 sera from healthy donors as the negative control group showed all negative results. We found that sensitivity, specificity, positive predictive value and negative predictive value were 75% (95% CI, 73.6 to 76.4%), 92.9% (95% CI, 91.5 to 94.4%), 40.9% (95% CI,39.5 to 42.3%) and 98.3% (95% CI, 96.8 to 99.6%), respectively.

CONCLUSION

The results showed that Dot-ELISA using CHM1 antigen has a potential for rapid and simple performance to detect antibody in serum of cholangiocarcinoma patients.